Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial for PRS-343 Plus Anti-PD-L1 Immunotherapy
pharmaceutical investing Pieris Pharmaceuticals Appoints Ingmar Bruns, M.D., Ph.D., as Vice President of Clinical Development
QIMC Identifies Three Fault-Controlled Helium Zones at New Salem-Apple River, Nova Scotia, and Expands Seismic Program to Approximately 50 Line-Kilometres
Flow Metals Identifies Widespread Epithermal Alteration and District-scale Structural Controls at Sixtymile
